← Back to Search

Other

Meibomian Gland Probing for Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis

N/A
Waitlist Available
Research Sponsored by Massachusetts Eye and Ear Infirmary
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients must be adults (18 years of age or older)
Patients must have evidence of Meibomitis
Must not have
Patients under the age of 18
Patients beyond the sub-acute phase of SJS
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights

Summary

This trial will study the effects of meibomian gland expression on people with SJS/TEN. The primary outcome is meibography, and the secondary outcome is patient symptoms. The investigators hypothesize that meibomian gland expression will improve symptoms in those patients.

Who is the study for?
Adults over 18 with Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) who are in the sub-acute phase (within 6 months of onset) and have meibomitis can participate. Those under 18, past the sub-acute phase, without meibomitis, or with unconfirmed SJS vs. other conditions cannot join.
What is being tested?
The trial is testing if mechanically expressing meibomian glands improves eyelid disease and ocular surface health for patients in the early stages of SJS/TEN. Health will be measured by imaging gland caliber before and after treatment, plus a follow-up at six months.
What are the potential side effects?
Potential side effects may include discomfort during mechanical expression of glands, temporary eye irritation or redness post-treatment. Specific side effect risks will depend on individual patient reactions to the procedure.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.
Select...
I have been diagnosed with Meibomitis.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am younger than 18 years old.
Select...
My Stevens-Johnson syndrome is no longer in the early stages.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Meibomian gland imaging (Meibography) - Qualitative description
Secondary study objectives
Ocular Surface Disease Index survey

Find a Location

Who is running the clinical trial?

Massachusetts Eye and Ear InfirmaryLead Sponsor
108 Previous Clinical Trials
13,004 Total Patients Enrolled
1 Trials studying Meibomian Gland Dysfunction
60 Patients Enrolled for Meibomian Gland Dysfunction

Media Library

Meibomian Gland Probing (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05145959 — N/A
Meibomian Gland Dysfunction Research Study Groups:
Meibomian Gland Dysfunction Clinical Trial 2023: Meibomian Gland Probing Highlights & Side Effects. Trial Name: NCT05145959 — N/A
Meibomian Gland Probing (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05145959 — N/A
~8 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top